Compounded NAD+ Injection

NAD+ is a coenzyme present in every cell. It is essential for converting food into ATP in the mitochondria and is the required substrate for sirtuin and PARP enzyme families that regulate DNA repair, gene expression, and metabolic signaling. Tissue NAD+ levels fall measurably with age — by roughly 50% between young adulthood and age 60 — driven by lower synthesis, higher consumption from chronic DNA damage and inflammation, and increased activity of NAD+-degrading enzymes like CD38. The clinical rationale for NAD+ replacement is restoring substrate availability for these aging-relevant pathways.

IV NAD+ delivers a large dose (typically 250–1000 mg) over a multi-hour clinic infusion. Subcutaneous injection delivers smaller doses (50–200 mg) at home, 2–3 times per week. SC absorption is slower and gentler — flushing and nausea are usually milder than IV — and the cumulative weekly delivery is comparable. SC is the standard telehealth route because it removes the chair time, the IV access, and the cost of clinic infusions, while still raising tissue NAD+ levels through consistent dosing.

Energy and mental-clarity changes are typically reported within 1–3 weeks of consistent dosing. Sleep and recovery improvements often follow at 3–6 weeks. The longer-term cellular benefits — sirtuin and DNA-repair effects — are not subjectively felt and are inferred from mechanism. Individual response varies based on baseline NAD+ status, age, sleep quality, and overall metabolic health.

Some patients combine injectable NAD+ with oral precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside), which the body converts into NAD+. The injection delivers NAD+ directly to the bloodstream; oral precursors raise the supply pool more gradually. There is no major interaction concern, but doubling up rarely doubles the effect and may not be cost-effective. Discuss any stack with your prescribing doctor before adding oral precursors.

NAD+ has been used clinically for decades, originally in addiction-recovery infusions, and has a generally favorable safety profile at standard subcutaneous doses. The most common considerations are flushing, nausea, and injection-site reactions, which usually resolve with slower injection and titration. The most important contraindication is active or recent malignancy, since NAD+ is required for cell proliferation as well as repair. Routine 8-on / 2-off cycling is common to allow reassessment and limit habituation.

NAD+ injection is the highest-bioavailability route — the coenzyme reaches systemic circulation directly. NAD+ nasal spray offers needle-free dosing with faster onset than oral routes and bypasses first-pass metabolism, but at lower systemic levels per dose. NAD+ face cream is topical and targeted to skin-cell metabolism rather than systemic NAD+ status. They serve different goals: injection for systemic cellular energy, nasal spray for convenient daily maintenance, face cream for skin-specific use.

There is no consistent evidence that an IV loading dose improves long-term outcomes versus starting subcutaneous and titrating up. Some patients choose a clinic IV for the experience or for a faster initial subjective response, but it is not required and adds significant cost. Starting low subcutaneously and titrating is the standard telehealth approach and is what your prescribing doctor will typically recommend.

Peptide12 partners with state-licensed compounding pharmacies that hold state and federal licensure and undergo regular USP <797> sterility audits. Every batch is third-party tested for identity, potency, sterility, and endotoxin before release. Compounded NAD+ is not FDA-approved as a finished drug product but is prepared from FDA-regulated active pharmaceutical ingredient under individualized prescription.